Ternary Therapeutics Raises €4.1M To Develop AI-Designed Molecular Glue Drugs

The round was led by European venture firm daphni, with participation from Pace Ventures, the i&i Biotech Fund, and the UK Innovation & Science Seed Fund, managed by Future Planet Capital.

Founded in 2024, Ternary Therapeutics is building a platform that combines machine learning, physics-based molecular modelling, and rapid lab testing to design molecular glues drugs that can target proteins previously considered undruggable.

While the field has produced several multi-billion-euro biotech companies, most molecular glues have historically been discovered by chance rather than intentional design. Ternary aims to change this by turning discovery into a repeatable, engineering-driven process.

Read Also - Choice Secures $7.1M In Series A Round To Grow Restaurant Tech In Europe

Its AI models predict protein behaviour and identify molecules that can bring them together. These are tested in the lab, with results fed back into the system to improve accuracy over time.

The company has already developed a pipeline of preclinical programmes focused on inflammatory and neuroinflammatory diseases, and has secured early research collaborations with pharmaceutical and biotech partners.

The new funding will support the expansion of Ternary’s computational and laboratory teams and help advance its lead programmes toward preclinical development.

Many disease-driving proteins lack clear drug-binding sites, limiting traditional treatments. Molecular glues address this by enabling new interactions between proteins. If designed reliably, platforms like Ternary’s could unlock new drug targets and create partnership opportunities with major pharmaceutical companies.

Dr Chris Tame, co-founder and Chief Executive of Ternary Therapeutics, says: “Molecular glues have delivered some of the most exciting breakthroughs in drug discovery over the past decade, but historically they’ve been discovered largely by chance rather than through a systematic process.

“Our platform is designed to change that by combining physics-informed AI with rapid experimental validation to engineer these molecules intentionally and at scale. That allows us to approach drug discovery more like an engineering problem than a process of trial and error.”

About Ternary Therapeutics

Ternary Therapeutics is a biotech startup developing an AI driven platform to design molecular glue therapeutics. By enabling targeted interactions between proteins it aims to unlock treatments for previously “undruggable” diseases. Its approach transforms drug discovery into a systematic scalable process opening new possibilities for innovative therapies and pharmaceutical partnerships.